The effects of acarbose therapy on reductions of myocardial infarction and all-cause death in T2DM during 10-year multifactorial interventions (The Beijing Community Diabetes Study 24)
机构：[1]Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, 1 Dong Jiao Min Xiang, Beijing 100730, China临床科室内分泌科首都医科大学附属北京同仁医院首都医科大学附属同仁医院[2]Medical Records and Statistics Department, Beijing Ditan Hospital, Capital Medical University, Beijing, China[3]Department of Endocrinology, Beijing Friendship Hospital, Capital Medical University, Beijing, China首都医科大学附属北京友谊医院[4]Jinsong Community Health Service Center, Beijing, China[5]Xinjiekou Community Health Service Center, Beijing, China[6]Aerospace Central Hospital, Beijing, China[7]Sanlitun Community Health Service Center, Beijing, China[8]Jiangtai Community Health Service Center, Beijing, China[9]Majiapu Community Health Service Center, Beijing, China
To investigate the potential benefits of acarbose therapy on cardiovascular events (CVD) in Type 2 diabetes (T2DM) in an urban community over 10-year follow-up. The study population of Beijing Community Diabetes Study (BCDS) were type 2 diabetes (T2DM) living in 21 communities in Beijing. All patients received comprehensive intervention in accordance with the Chinese guidelines for the prevention and treatment of diabetes. Professors in endocrinology from top tier hospitals regularly visited the communities for consultations, which was a feature of this study. A total of 1797 T2DM in BCDS study had complete screening data, including blood glucose, blood pressure, lipid profiles and acarbose continuous therapy. After 10-year follow-up, the risks of CVD outcomes were assessed according to whether patients had received acarbose therapy or not. All patients were followed-up to assess the long-term effects of the multifactorial interventions. At baseline, compared with the acarbose therapy free in T2DM, there was no significant difference in achieving the joint target control in patients with acarbose therapy. From the beginning of 8th year follow-up, the joint target control rate in patients with acarbose therapy was significantly higher than that of acarbose therapy free. During the 10-year follow-up, a total of 446 endpoint events occurred, including all-cause death, cardiovascular events, cerebrovascular events. The incidences of myocardial infarction (from the 4th year of follow-up) and all-cause death (from the 2nd year of follow-up) in patients who received acarbose therapy were significantly lower than that of acarbose therapy free respectively. In Cox multivariate analyses, there were significant differences in incidences of myocardial infarction and all-cause death between afore two groups during the 10-year follow-up, and the adjusted HRs were 0.50 and 0.52, respectively. After multifactorial interventions, T2DM with acarbose therapy revealed significant reductions of myocardial infarction and all-cause death. The long-term effects of with acarbose therapy on improving joint target control might be one of the main reasons of myocardial infarction and all-cause death reduction.Trial Registration: ChiCTR-TRC-13003978, ChiCTR-OOC-15006090.
基金：
Capital Medical Development Foundation of China (2007-1035), a Grant of
Special Scientifc Research on Capital Health Development (2011-2005-01, 2016-1-2057, 2016-2-2054), Beijing
Municipal Science & Technology Commission (Z151100004015021), BRIDGES Grant from the International
Diabetes Federation (ST12-024).
第一作者机构：[1]Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, 1 Dong Jiao Min Xiang, Beijing 100730, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Xue‑Lian Zhang,Shen‑YuanYuan,Gang Wan,et al.The effects of acarbose therapy on reductions of myocardial infarction and all-cause death in T2DM during 10-year multifactorial interventions (The Beijing Community Diabetes Study 24)[J].SCIENTIFIC REPORTS.2021,11(1):doi:10.1038/s41598-021-84015-0.
APA：
Xue‑Lian Zhang,Shen‑YuanYuan,Gang Wan,Ming‑XiaYuan,Guang‑RanYang...&Ying‑jun Chen.(2021).The effects of acarbose therapy on reductions of myocardial infarction and all-cause death in T2DM during 10-year multifactorial interventions (The Beijing Community Diabetes Study 24).SCIENTIFIC REPORTS,11,(1)
MLA：
Xue‑Lian Zhang,et al."The effects of acarbose therapy on reductions of myocardial infarction and all-cause death in T2DM during 10-year multifactorial interventions (The Beijing Community Diabetes Study 24)".SCIENTIFIC REPORTS 11..1(2021)
